TY - JOUR
T1 - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management
AU - Groh, Matthieu
AU - Pagnoux, Christian
AU - Baldini, Chiara
AU - Bel, Elisabeth
AU - Bottero, Paolo
AU - Cottin, Vincent
AU - Dalhoff, Klaus
AU - Dunogué, Bertrand
AU - Gross, Wolfgang
AU - Holle, Julia
AU - Humbert, Marc
AU - Jayne, David
AU - Jennette, J. Charles
AU - Lazor, Romain
AU - Mahr, Alfred
AU - Merkel, Peter A.
AU - Mouthon, Luc
AU - Sinico, Renato Alberto
AU - Specks, Ulrich
AU - Vaglio, Augusto
AU - Wechsler, Michael E.
AU - Cordier, Jean François
AU - Guillevin, Loïc
N1 - Funding Information:
David Jayne: research grants from Genzyme and Roche/Genentech; consultancy for Aurinia, Biogen, Chemocentryx, GSK, Lilly and Medimmune, Merck Serono and Roche/Genentech.
Funding Information:
Peter Merkel: research grants from Bristol-Myers Squibb, Celgene, Genentech/Roche and GSK; consulting fees from Actelion, GSK and Sanofi.
Funding Information:
Loïc Guillevin: Member of the Advisory Board that designed an EGPA mepolizumab trial; member of the Scientific Council of the AIR registry, funded by Roche Laboratory; lecture fees paid by LFB, Roche Pharma and CSL Behring; Roche Laboratory partially provided rituximab for the MAINRITSAN trial (National PHRC No. 2008-002846-51) comparing rituximab vs. azathioprine as maintenance therapy for ANCA-associated vasculitides.
Publisher Copyright:
© 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.
AB - Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.
UR - http://www.scopus.com/inward/record.url?scp=84941599615&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2015.04.022
DO - 10.1016/j.ejim.2015.04.022
M3 - Journal articles
C2 - 25971154
AN - SCOPUS:84941599615
SN - 0953-6205
VL - 26
SP - 545
EP - 553
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
IS - 7
ER -
